A prevalent hormonal condition affecting 1 in 8 women, previously called Polycystic Ovary Syndrome (PCOS), has been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change, announced after 14 years of expert and patient collaboration, aims to better reflect the condition's metabolic and endocrine nature, improve care, and raise awareness about its wide-ranging impact on health, fertility, and metabolism.
The hormonal condition affecting one in eight women worldwide, formerly known as Polycystic Ovary Syndrome (PCOS), has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). This significant name change, which was published in The Lancet, is the result of 14 years of collaboration between medical experts and patients, with the goal of improving care and accurately reflecting the condition's complexities. PMOS is characterized by fluctuating hormones that can significantly impact weight, metabolic and mental health, the reproductive system, and skin. It is closely associated with metabolic syndrome, which increases the risk of serious health issues like Type 2 diabetes, heart disease, and stroke. While the exact cause remains unknown, evidence suggests genetics and obesity play roles. Symptoms of PMOS vary, making diagnosis challenging. Common indicators include irregular menstrual cycles and an excess production of androgens, which can lead to acne, hair growth, or thinning. It may also cause follicles on the ovaries, though these are not abnormal cysts. For teenagers, diagnosis typically requires both irregular periods and signs of high androgens, such as elevated blood hormone levels or severe acne. PMOS is a leading cause of female infertility due to infrequent ovulation and can also increase the risk of certain pregnancy complications like gestational diabetes or preterm birth, though most individuals with the condition can still successfully carry a pregnancy. Treatment for PMOS often begins with lifestyle changes, including a healthier diet, regular exercise, and adequate sleep. These changes are crucial because, for many women with PMOS, excess insulin confuses the ovaries, leading to overproduction of testosterone, which causes many of the symptoms. Other treatments include insulin-sensitizing medicines like Metformin, medications that block androgens, and hormonal birth control. Experts emphasize that management should be individualized to address specific symptoms and patient goals, such as fertility or symptom control. The medical community is actively disseminating information about the name change, hoping it will foster greater awareness and lead to more effective patient care.
